



## PRIOR AUTHORIZATION POLICY

- POLICY:** Hepatitis C – Viekira Pak Prior Authorization Policy
- Viekira Pak™ (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets [co-packaged] – AbbVie)

**REVIEW DATE:** 09/13/2023

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

### CIGNA NATIONAL FORMULARY COVERAGE:

#### OVERVIEW

Viekira Pak contains ombitasvir, a hepatitis C virus (HCV) NS5A inhibitor, paritaprevir, an HCV NS3/4A protease inhibitor, ritonavir, a cytochrome P450 (CYP)3A inhibitor and dasabuvir, an HCV non-nucleoside NS5B polymerase inhibitor.<sup>1</sup>

Viekira Pak is indicated for the treatment of patients with **genotype 1 chronic HCV** infection.<sup>1</sup> Viekira Pak is indicated in patients with:

- Genotype 1b without cirrhosis or with compensated cirrhosis; or
- Genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.

The recommended dose of Viekira Pak is two co-formulated ombitasvir/paritaprevir/ritonavir tablets once daily (in the morning) and one dasabuvir tablet twice daily (morning and evening). When administered with Viekira Pak, the recommended dose of ribavirin is weight-based. For patients with HCV/human immunodeficiency virus (HIV)-1 co-infection the recommendations are the same as for those without co-infection. Of note, product labeling notes that some patients with genotype 1a with cirrhosis may be treated for 12 weeks with Viekira Pak + weight-based ribavirin based on data from the TURQUOISE-II trial. In liver

transplant recipients with normal hepatic function and mild fibrosis (Metavir fibrosis score  $\leq 2$ ), the recommended duration of therapy with Viekira Pak is 24 weeks, irrespective of HCV genotype 1 subtype.

**Table 1. FDA-Approved Regimens and Treatment Duration for Viekira Pak.<sup>1</sup>**

Patient Population	Treatment*	Duration
Genotype 1a, without cirrhosis	Viekira Pak + WBR	12 weeks
Genotype 1a, with cirrhosis	Viekira Pak + WBR	24 weeks**
Genotype 1b, with or without cirrhosis	Viekira Pak	12 weeks

\* Note: Follow the genotype 1a dosing recommendations in patients with an unknown genotype 1 subtype or with mixed genotype 1 infection; WBR – Weight-based ribavirin; \*\* A 12 week treatment duration may be considered for some patients based on prior treatment history.

## Guidelines

Viekira Pak is not addressed in the American Association for the Study of Liver Diseases (AASLD) Guidelines recommended (or alternative) regimens.<sup>2</sup> It has been supplanted by other direct-acting antivirals.

## POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Viekira Pak. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Viekira Pak as well as the monitoring required for adverse events and efficacy, approval requires Viekira Pak to be prescribed by or in consultation with a physician who specializes in the condition being treated.

- **Viekira Pak™ (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets [co-packaged] – AbbVie)**

**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

## FDA-Approved Indications

- 1. Chronic Hepatitis C Virus (HCV), Genotype 1a.** Approve for the duration noted if the patient meets the following (A, B, C, and D):
  - A)** Patient is  $\geq 18$  years of age; AND
  - B)** Patient meets ONE of the following (i or ii):
    - i.** Patient does not have cirrhosis: Approve for 12 weeks; OR
    - ii.** Patient has cirrhosis: Approve for 24 weeks; AND
  - C)** The medication is prescribed in combination with ribavirin; AND
  - D)** The medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician.
- 2. Chronic Hepatitis C Virus (HCV), Genotype 1b.** Approve for 12 weeks if the patient meets the following (A and B):

- A) Patient is  $\geq$  18 years of age; AND
- B) The medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician.

**3. Recurrent Hepatitis C Virus (HCV) Post-Liver Transplantation, Genotype**

**1.** Approve for 24 weeks if the patient meets the following (A, B, and C):

- A) Patient is  $\geq$  18 years of age; AND
- B) The medication is prescribed in combination with ribavirin; AND
- C) The medication is prescribed by or in consultation with one of the following prescribers who is affiliated with a transplant center: a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician.

**4. Patient Has Been Started on Viekira Pak.** Approve Viekira Pak for an indication or condition addressed as an approval in the Recommended Authorization Criteria section (FDA-Approved Indications). Approve the duration described above to complete a course of therapy (e.g., a patient who should receive 12 weeks, and has received 3 weeks should be approved for 9 weeks to complete their 12-week course).

**CONDITIONS NOT COVERED**

- **Viekira Pak™ (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets [co-packaged] – AbbVie)** is(are) considered experimental, investigational or unproven for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

**1. Hepatitis C Virus (HCV), Child-Pugh Class B or Child-Pugh Class C Liver Disease (Moderate or Severe Hepatic Impairment).** Viekira Pak is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh Class B or C).<sup>1</sup> The AASLD recommend *against* the use of Viekira Pak in patients with chronic HCV with decompensated cirrhosis (Child-Pugh Class B or C).

**2. Hepatitis C Virus (HCV) [Any Genotype], Combination with Any Other Direct-Acting Antivirals (DAAs) Not Including Ribavirin.** Viekira Pak provides a complete antiviral regimen for patients with genotype 1 HCV. Viekira Pak is indicated with ribavirin for some patients. In the opinion of a specialist physician reviewing the data we have adopted this criterion.

**3. Life Expectancy Less Than 12 Months Due to Non-Liver Related Comorbidities.** Patients with limited life expectancy for whom HCV therapy would not improve symptoms or prognosis do not require treatment.<sup>2</sup> According to AASLD guidance, the panel continues to recommend treatment for all patients with chronic HCV infection, *except* those with short life expectancies that cannot be remediated by treating HCV, by transplantation, or by other directed therapy.

For these patients, the benefits of HCV treatment are unlikely to be realized, and palliative care strategies should take precedence.

**5. Pediatric Patients (Age < 18 Years).** The safety and efficacy of Viekira Pak have not been established in pediatric patients < 18 years of age.<sup>1</sup>

**6. Retreatment with Viekira Pak in Patients Who Have Previously Received Viekira Pak, Viekira XR, or Technivie** (e.g., retreatment in prior null responders, prior partial responders, prior relapse patients, patients who have not completed a course of therapy due to an adverse reaction or for other reasons). Technivie, Viekira Pak, and Viekira XR contain the same active ingredients; Viekira Pak and Viekira XR additionally contain dasabuvir.

**REFERENCES**

1. Viekira Pak™ tablets [prescribing information]. North Chicago, IL: AbbVie; December 2019.
2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Testing, managing, and treating hepatitis C. Available at: <http://www.hcvguidelines.org>. Updated October 24, 2022. Accessed on August 17, 2023.

**HISTORY**

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	09/14/2022
Annual Revision	No criteria changes.	09/13/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna